Miller, RE;
Crusz, SM;
Ledermann, JA;
(2019)
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Future Oncology
, 15
(16)
pp. 1845-1853.
10.2217/fon-2019-0057.
Preview |
Text
Ledermann_Olaparib maintenance for first-line treatment of ovarian cancer. Will SOLO1 reset the standard of care_AAM.pdf - Accepted Version Download (401kB) | Preview |
Abstract
Maintenance therapy with PARP inhibitors has heralded a new era in the management of recurrent epithelial ovarian cancer. The greatest effect is seen in women with BRCA1/2 tumors but those without this mutation also benefit. However, in most patients, the drugs eventually fail to prevent progression, so alternative strategies are needed. The SOLO1 trial randomized women with BRCA1/2-mutated advanced ovarian cancer to olaparib or placebo maintenance after first-line chemotherapy. Olaparib significantly improved progression-free survival to a degree that has not been seen in other first-line trials in ovarian cancer. This landmark trial is likely to change practice for this group of women. Here, we focus on the SOLO1 results in the context of the current management of advanced ovarian cancer.
| Type: | Article |
|---|---|
| Title: | Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care? |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/fon-2019-0057 |
| Publisher version: | https://doi.org/10.2217/fon-2019-0057 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | mutation, PARP inhibitor, SOLO1, olaparib, ovarian cancer |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10074275 |
Archive Staff Only
 |
View Item |
